Bowen Acquisition CORP 10-Q quarterly reports

Bowen Acquisition Corp's Q2 2026 report highlights substantial doubt about its ability to continue as a going concern, despite a net income of $1.09 million, due to ongoing operational costs and the pending business combination.

Bowen Acquisition Corp's Q1 2026 10-Q filing reveals significant going concern uncertainties and a pending business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.

Bowen Acquisition Corp reports significant financial losses and a Nasdaq delisting decision after failing to complete its business combination with Qianzhi.

Bowen Acquisition Corp reported a significant decline in its trust account due to high redemptions and received multiple Nasdaq delisting notices, raising substantial doubt about its ability to continue as a going concern.

Bowen Acquisition Corp reported a substantial net loss of over $2 million for the first quarter of 2025, primarily driven by costs associated with its pending business combination and a significant reduction in its trust account due to shareholder redemptions, while also facing a Nasdaq non-compliance notice for a delayed filing.

Bowen Acquisition Corp reported a net income of $2.4 million for the nine months ended September 30, 2024, primarily driven by interest earned on its trust account, while continuing its efforts to complete a business combination.

Bowen Acquisition Corp reported a net income of $1.6 million for the first six months of 2024, primarily driven by interest earned on its trust account, while actively pursuing a business combination.

Bowen Acquisition Corp reported a net income of $786,362 for the first quarter of 2024, primarily due to interest earned on its trust account.